Top

International Ophthalmology

Published in:

Open Access 01-12-2024 | Simvastatin | Original Paper

Anti-inflammatory potential of simvastatin and amfenac in ARPE-19 cells; insights in preventing re-detachment and proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery

Authors: Niina Harju, Maria Hytti, Onni Kolari, Hilkka Nisula, Sirpa Loukovaara, Anu Kauppinen

Published in: International Ophthalmology | Issue 1/2024

Abstract

Purpose

Rhegmatogenous retinal detachment is a severe vision-threatening complication that can result into proliferative vitreoretinopathy (PVR) and re-detachment of the retina if recovery from surgery fails. Inflammation and changes in retinal pigment epithelial (RPE) cells are important contributors to the disease. Here, we studied the effects of simvastatin and amfenac on ARPE-19 cells under inflammatory conditions.

Methods

ARPE-19 cells were pre-treated with simvastatin and/or amfenac for 24 h after which interleukin (IL)-1α or IL-1β was added for another 24 h. After treatments, lactate dehydrogenase release, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) processing, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity, prostaglandin E2 (PGE2) level, and extracellular levels of IL-6, IL-8, monocytic chemoattractant protein (MCP-1), vascular endothelial growth factor (VEGF), and pigment epithelium-derived factor, as well as the production of reactive oxygen species (ROS) were determined.

Results

Pre-treatment of human ARPE-19 cells with simvastatin reduced the production of IL-6, IL-8, and MCP-1 cytokines, PGE2 levels, as well as NF-κB activity upon inflammation, whereas amfenac reduced IL-8 and MCP-1 release but increased ROS production. Together, simvastatin and amfenac reduced the release of IL-6, IL-8, and MCP-1 cytokines as well as NF-κB activity but increased the VEGF release upon inflammation in ARPE-19 cells.

Conclusion

Our present study supports the anti-inflammatory capacity of simvastatin as pre-treatment against inflammation in human RPE cells, and the addition of amfenac complements the effect. The early modulation of local conditions in the retina can prevent inflammation induced PVR formation and subsequent retinal re-detachment.

Available only for authorised users

Nagpal M, Chaudhary P, Wachasundar S, Eltayib A, Raihan A (2018) Management of recurrent rhegmatogenous retinal detachment. Indian J Ophthalmol 66:1763–1771. https://doi.org/10.4103/ijo.IJO_1212_18CrossRefPubMedPubMedCentral

Loukovaara S, Sahanne S, Takala A, Haukka J (2018) Statin use and vitreoretinal surgery: findings from a Finnish population-based cohort study. Acta Ophthalmol 96:442–451. https://doi.org/10.1111/aos.13641CrossRefPubMed

Idrees S, Sridhar J, Kuriyan AE (2019) Proliferative vitreoretinopathy: a review. Int Ophthalmol Clin 59:221–240. https://doi.org/10.1097/IIO.0000000000000258CrossRefPubMedPubMedCentral

Öhman T, Gawriyski L, Miettinen S, Varjosalo M, Loukovaara S (2021) Molecular pathogenesis of rhegmatogenous retinal detachment. Sci Rep 11:966. https://doi.org/10.1038/s41598-020-80005-wCrossRefPubMedPubMedCentral

Caceres PS, Rodriguez-Boulan E (2020) Retinal pigment epithelium polarity in health and blinding diseases. Curr Opin Cell Biol 62:37–45. https://doi.org/10.1016/j.ceb.2019.08.001CrossRefPubMed

Steel D (2014) Retinal detachment. BMJ Clin Evid 2014:0710PubMedPubMedCentral

Zacks DN, Johnson MW (2004) Transretinal pigment migration: an optical coherence tomographic study. Arch Ophthalmol 122:406–408. https://doi.org/10.1001/archopht.122.3.406CrossRefPubMed

Kaneko H, Terasaki H (2017) Biological involvement of MicroRNAs in proliferative vitreoretinopathy. Trans Vis Sci Tech 6:5. https://doi.org/10.1167/tvst.6.4.5CrossRef

Wooff Y, Man SM, Aggio-Bruce R, Natoli R, Fernando N (2019) IL-1 Family members mediate cell death, inflammation and angiogenesis in retinal degenerative diseases. Front Immunol 10:1618. https://doi.org/10.3389/fimmu.2019.01618CrossRefPubMedPubMedCentral

10.

Kataoka K, Matsumoto H, Kaneko H, Notomi S, Takeuchi K, Sweigard JH, Atik A, Murakami Y, Connor KM, Terasaki H, Miller JW, Vavvas DG (2015) Macrophage- and RIP3-dependent inflammasome activation exacerbates retinal detachment-induced photoreceptor cell death. Cell Death Dis 6:e1731–e1731. https://doi.org/10.1038/cddis.2015.73CrossRefPubMedPubMedCentral

11.

Bian Z-M, Field MG, Elner SG, Elner VM (2018) Expression and regulation of alarmin cytokine IL-1α in human retinal pigment epithelial cells. Exp Eye Res 172:10–20. https://doi.org/10.1016/j.exer.2018.03.015CrossRefPubMedPubMedCentral

12.

Piippo N, Korkmaz A, Hytti M, Kinnunen K, Salminen A, Atalay M, Kaarniranta K, Kauppinen A (2014) Decline in cellular clearance systems induces inflammasome signaling in human ARPE-19 cells. Biochim Biophys Acta 1843:3038–3046. https://doi.org/10.1016/j.bbamcr.2014.09.015CrossRefPubMed

13.

Limb GA, Litile BC, Meager A, Ogilvie JA, Wolstencroft RA, Franks WA, Chignell AH, Dumonde DC (1991) Cytokines in proliferative vitreoretinopathy. Eye 5:686–693. https://doi.org/10.1038/eye.1991.126CrossRefPubMed

14.

Kon CH, Occleston NL, Aylward GW, Khaw PT (1999) Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 40:705–712PubMed

15.

Aksünger A, Or M, Okur H, Hasanreisoğlu B, Akbatur H (1997) Role of interleukin 8 in the pathogenesis of proliferative vitreoretinopathy. Ophthalmologica 211:223–225. https://doi.org/10.1159/000310794CrossRefPubMed

16.

Mitamura Y, Takeuchi S, Yamamoto S, Yamamoto T, Tsukahara I, Matsuda A, Tagawa Y, Mizue Y, Nishihira J (2002) Monocyte chemotactic protein-1 levels in the vitreous of patients with proliferative vitreoretinopathy. Jpn J Ophthalmol 46:218–221. https://doi.org/10.1016/S0021-5155(01)00497-XCrossRefPubMed

17.

Chen X, Yang W, Deng X, Ye S, Xiao W (2020) Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway. Mol Vis 26:517–529PubMedPubMedCentral

18.

Talreja O, Kerndt CC, Cassagnol M (2022) Simvastatin. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK532919/

19.

Tersi N, Kassumeh S, Ohlmann A, Strehle L, Priglinger SG, Hartmann D, Wolf A, Wertheimer CM (2023) Pharmacological therapy of proliferative vitreoretinopathy: systematic in vitro comparison of 36 pharmacological agents. J Ocul Pharmacol Ther 39:148–158. https://doi.org/10.1089/jop.2022.0078CrossRefPubMed

20.

Mysore Y, del Amo EM, Loukovaara S, Hagström M, Urtti A, Kauppinen A (2021) Statins for the prevention of proliferative vitreoretinopathy: cellular responses in cultured cells and clinical statin concentrations in the vitreous. Sci Rep 11:980. https://doi.org/10.1038/s41598-020-80127-1CrossRefPubMedPubMedCentral

21.

Gilbert R, Al-Janabi A, Tomkins-Netzer O, Lightman S (2017) Statins as anti-inflammatory agents: a potential therapeutic role in sight-threatening non-infectious uveitis. Porto Biomed J 2:33–39. https://doi.org/10.1016/j.pbj.2017.01.006CrossRefPubMedPubMedCentral

22.

Ooi KG-J, Khoo P, Vaclavik V, Watson SL (2019) Statins in ophthalmology. Surv Ophthalmol 64:401–432. https://doi.org/10.1016/j.survophthal.2019.01.013CrossRefPubMed

23.

Lindstrom R, Kim T (2006) Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin 22:397–404. https://doi.org/10.1185/030079906X89775CrossRefPubMed

24.

Waterbury LD (2006) Ocular anti-inflammatory activity of amfenac relative to other nonsteroidal anti-inflammatory agents. FASEB J 20:A1127–A1127. https://doi.org/10.1096/fasebj.20.5.A1127-cCrossRef

25.

Yanni SE, Clark ML, Yang R, Bingaman DP, Penn JS (2010) The effects of nepafenac and amfenac on retinal angiogenesis. Brain Res Bull 81:310–319. https://doi.org/10.1016/j.brainresbull.2009.10.018CrossRefPubMed

26.

Chastain JE, Sanders ME, Curtis MA, Chemuturi NV, Gadd ME, Kapin MA, Markwardt KL, Dahlin DC (2016) Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye. Exp Eye Res 145:58–67. https://doi.org/10.1016/j.exer.2015.10.009CrossRefPubMed

27.

Loukovaara S, Haukka J (2022) Association between NSAID and statin therapy and the incidence of intravitreal anti-vascular endothelial growth factor injections and Nd:YAG laser treatment after cataract surgery in Finland. J Ophthalmic Vis Res 17:186–195. https://doi.org/10.18502/jovr.v17i2.10789CrossRefPubMedPubMedCentral

28.

Bhattarai N, Korhonen E, Toppila M, Koskela A, Kaarniranta K, Mysore Y, Kauppinen A (2020) Resvega alleviates hydroquinone-induced oxidative stress in arpe-19 cells. Int J Mol Sci 21:2066. https://doi.org/10.3390/ijms21062066CrossRefPubMedPubMedCentral

29.

Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254. https://doi.org/10.1016/0003-2697(76)90527-3CrossRefPubMed

30.

Bhattarai N, Korhonen E, Mysore Y, Kaarniranta K, Kauppinen A (2021) Hydroquinone induces NLRP3-independent IL-18 release from ARPE-19 cells. Cells 10:1405. https://doi.org/10.3390/cells10061405CrossRefPubMedPubMedCentral

31.

Dinarello CA (2018) Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev 281:8–27. https://doi.org/10.1111/imr.12621CrossRefPubMedPubMedCentral

32.

Candar T, Asena L, Alkayid H, Altınörs DD (2020) Galectin-3, IL-1A, IL-6, and EGF levels in corneal epithelium of patients with recurrent corneal erosion syndrome. Cornea 39:1354–1358. https://doi.org/10.1097/ICO.0000000000002422CrossRefPubMed

33.

Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM (2000) Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assess Anti Inflam Effic Inflam 24:357–370. https://doi.org/10.1023/a:1007049015148

34.

Aoki T, Frȍsen J, Fukuda M, Bando K, Shioi G, Tsuji K, Ollikainen E, Nozaki K, Laakkonen J, Narumiya S (2017) Prostaglandin E2–EP2–NF-κB signaling in macrophages as a potential therapeutic target for intracranial aneurysms. Sci Signal. https://doi.org/10.1126/scisignal.aah6037CrossRefPubMedPubMedCentral

35.

Sio SWS, Ang SF, Lu J, Moochhala S, Bhatia M (2010) Substance P upregulates cyclooxygenase-2 and prostaglandin E metabolite by activating ERK1/2 and NF-κB in a mouse model of burn-induced remote acute lung injury. J Immunol 185:6265–6276. https://doi.org/10.4049/jimmunol.1001739CrossRefPubMed

36.

Kawabata A (2011) Prostaglandin E2 and pain-an update. Biol Pharm Bull 34:1170–1173. https://doi.org/10.1248/bpb.34.1170CrossRefPubMed

37.

Singh R, Alpern J, Lehmann L, Reiser S, Walters S (2012) Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol 2012:1259–1269. https://doi.org/10.2147/OPTH.S31902CrossRef

38.

Elisia I, Nakamura H, Lam V, Hofs E, Cederberg R, Cait J, Hughes MR, Lee L, Jia W, Adomat HH, Guns ES, McNagny KM, Samudio I, Krystal G (2016) DMSO represses inflammatory cytokine production from human blood cells and reduces autoimmune arthritis. PLoS ONE 11:e0152538. https://doi.org/10.1371/journal.pone.0152538CrossRefPubMedPubMedCentral

39.

Matsushima K, Yang D, Oppenheim JJ (2022) Interleukin-8: an evolving chemokine. Cytokine 153:155828. https://doi.org/10.1016/J.CYTO.2022.155828CrossRefPubMed

40.

Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29:313–326. https://doi.org/10.1089/jir.2008.0027CrossRefPubMedPubMedCentral

41.

Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S (2006) Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 20:1366–1369. https://doi.org/10.1038/sj.eye.6702138CrossRefPubMed

42.

Asensio-Sánchez VM, Collazos JM, Cantón M (2015) Interleukin-6 concentrations in the vitreous body of patients with retinal detachment. Arch Soc Esp Oftalmol 90:527–530. https://doi.org/10.1016/j.oftal.2015.03.006CrossRefPubMed

43.

Roh MI, Murakami Y, Thanos A, Vavvas DG, Miller JW (2011) Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment. IOVS 52:3825–3831. https://doi.org/10.1167/iovs.10-6797CrossRef

44.

He L, He T, Farrar S, Ji L, Liu T, Ma X (2017) Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem 44:532–553. https://doi.org/10.1159/000485089CrossRefPubMed

45.

Ford KM, Saint-Geniez M, Walshe T, Zahr A, D’Amore PA (2011) Expression and role of VEGF in the adult retinal pigment epithelium. IOVS 52:9478–9487. https://doi.org/10.1167/iovs.11-8353CrossRef

46.

Zhang SX, Wang JJ, Gao G, Parke K, Ma J (2006) Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF–VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 37:1–12. https://doi.org/10.1677/jme.1.02008CrossRefPubMed

47.

Wang Y, Subramanian P, Shen D, Tuo J, Becerra SP, Chan C-C (2013) Pigment epithelium-derived factor reduces apoptosis and pro-inflammatory cytokine gene expression in a murine model of focal retinal degeneration. ASN Neuro. https://doi.org/10.1042/AN20130028CrossRefPubMedPubMedCentral

48.

Sene A, Apte RS (2018) Inflammation-induced photoreceptor cell death. Adv Exp Med Biol 1074:203–208. https://doi.org/10.1007/978-3-319-75402-4_25CrossRefPubMed

49.

Balogh A, Milibák T, Szabó V, Nagy ZZ, Kaarniranta K, Resch MD (2020) Immunological biomarkers of the vitreous responsible for proliferative alteration in the different forms of retinal detachment. BMC Ophthalmol 20:491. https://doi.org/10.1186/s12886-020-01745-xCrossRefPubMedPubMedCentral

50.

Rasier R, Gormus U, Artunay O, Yuzbasioglu E, Oncel M, Bahcecioglu H (2010) Vitreous levels of VEGF, IL-8, and TNF-α in retinal detachment. Curr Eye Res 35:505–509. https://doi.org/10.3109/02713681003597248CrossRefPubMed

51.

Chong DY, Boehlke CS, Zheng Q-D, Zhang L, Han Y, Zacks DN (2008) Interleukin-6 as a photoreceptor neuroprotectant in an experimental model of retinal detachment. Invest Ophthalmol Vis Sci. https://doi.org/10.1167/iovs.07-1641CrossRefPubMed

52.

Danielescu C, Zugun-Eloae F, Zlei M (2016) Concentrations of vitreal cytokines in rhegmatogenous retinal detachment. Rev Med Chir Soc Med Nat Iasi 120:124–129PubMed

53.

Tang M, Wang Y, Han S, Guo S, Xu N, Guo J (2013) Endogenous PGE2 induces MCP-1 expression via EP4/p38 MAPK signaling in melanoma. Oncol Lett 5:645–650. https://doi.org/10.3892/ol.2012.1047CrossRefPubMed

54.

Nakayama T, Mutsuga N, Yao L, Tosato G (2005) Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells. J Leukoc Biol 79:95–104. https://doi.org/10.1189/jlb.0405226CrossRefPubMed

55.

Clanton TL (2007) Hypoxia-induced reactive oxygen species formation in skeletal muscle. J Appl Physiol 102:2379–2388. https://doi.org/10.1152/japplphysiol.01298.2006CrossRefPubMed

56.

Di Meo S, Reed TT, Venditti P, Victor VM (2016) Harmful and beneficial role of ROS. Oxid Med Cell Longev 2016:1–3. https://doi.org/10.1155/2016/7909186CrossRef

57.

Chan TCW, Wilkinson Berka JL, Deliyanti D, Hunter D, Fung A, Liew G, White A (2020) The role of reactive oxygen species in the pathogenesis and treatment of retinal diseases. Exp Eye Res 201:108255. https://doi.org/10.1016/j.exer.2020.108255CrossRefPubMed

58.

Bromeo AJ, Veloso A, Lerit SJ, Gomez MC (2021) Tractional retinal detachment (‘crunch’ phenomenon) from intravitreal anti-vascular endothelial growth factor injection in central retinal vein occlusion. BMJ Case Rep 14:e240506. https://doi.org/10.1136/bcr-2020-240506CrossRefPubMedPubMedCentral

59.

Marneros AG (2016) Increased VEGF-A promotes multiple distinct aging diseases of the eye through shared pathomechanisms. EMBO Mol Med 8:208–231. https://doi.org/10.15252/emmm.201505613CrossRefPubMedPubMedCentral

60.

Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, Kuppermann B, Kenney M (2013) Diabetic retinopathy and VEGF. Open Ophthalmol J 7:4–10. https://doi.org/10.2174/1874364101307010004CrossRefPubMedPubMedCentral

61.

Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J (2001) Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 489:270–276. https://doi.org/10.1016/S0014-5793(01)02110-XCrossRefPubMed

Title: Anti-inflammatory potential of simvastatin and amfenac in ARPE-19 cells; insights in preventing re-detachment and proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery
Authors: Niina Harju
Maria Hytti
Onni Kolari
Hilkka Nisula
Sirpa Loukovaara
Anu Kauppinen
Publication date: 01-12-2024
Publisher: Springer Netherlands
Keywords: Simvastatin
Retinal Detachment
Cytokines
Published in: International Ophthalmology / Issue 1/2024
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-024-03067-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anti-inflammatory potential of simvastatin and amfenac in ARPE-19 cells; insights in preventing re-detachment and proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Interferons in vitreoretinal diseases; a review on their clinical application, and mechanism of action

Determination of the toric axis by using internal astigmatism axis in non-dilated eyes

In vivo assessment of the ocular biomechanical properties in patients with idiopathic normal pressure hydrocephalus

A comparison of conventional and accelerated corneal crosslinking: corneal epithelial remodeling and in vivo confocal microscopy analysis

LASIK is associated with early cataract surgery in healthy patients

Long-term clinical outcomes of patients with sympathetic ophthalmia